Associate Scientist II

Summary: We are seeking a motivated, organized, and enthusiastic Associate Scientist II to join Ascidian's team. Working closely with our R&D Scientists and Associates, you will help establish and validate molecular biology and protein biochemistry assays critical to our gene therapy discovery platform. This is an exciting opportunity to work with and learn from a variety of teams in a small, fast-paced biotechnology company. The successful candidate will effectively work in a team-oriented environment and deliver high-quality data on a timeline. Responsibilities: Become a critical part of our gene therapy research workflow Plan and execute a variety of biochemistry and molecular biology assays to support drug development programs Maintain cell cultures and conduct cellular assays Perform independent data analysis and electronic notebook record keeping Effectively communicate progress and results to the team Collaborate and communicate across a diverse research team to progress scientific goals Qualifications: BS or MS in Biology, Biochemistry, or a related discipline and 1-3 years of laboratory research experience Ability to follow SOPs Proficient in cell and molecular biology techniques including nucleic acid preparation (DNA, RNA) and analysis (primer design, RT-qPCR/ddPCR) Experience with protein biochemistry and enzyme activity assays (Extraction, Western blot, etc.) Skilled in cell culture and cell-based functional assays Proficiency in molecular cloning (e.g., traditional, Golden Gate, Gibson, etc.) and molecular biology design tools (e.g., Benchling, SnapGene, etc.) Experience in NGS processes is a plus Passion for working at the bench to advance programs and solve technical challenges Self-motivation and adaptability to evolving project priorities and responsibilities Team-oriented, with a strong work ethic Salary: $ 77,300 to $87,600 per year. The final salary offer will be determined based on several factors, including the candidate’s relevant experience, specific skills, and internal equity.